Editas Medicine Inc (NASDAQ: EDIT) has reported E.P.S. of $-0.82 for its second fiscal quarter (ending June 30) versus $-0.56 for the same period a year ago. This performance was $-0.11 short of the consensus estimate of $-0.71. For the latest four quarters through June 30, E.P.S. were $-2.36 compared to $-2.96 a year ago.
Recent Price Action
On 8/7/24, Editas Medicine Inc (NASDAQ: EDIT) stock suffered a major decline of -12.2%, closing at $4.11. Moreover, above average trading volume at 143% of normal accompanied the decline. The stock has declined -24.2% during the last week and has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to be in line with the cost of capital, EDIT is expected to continue to be Value Creation neutral.
Editas Medicine has a current Value Trend Rating of F (Lowest Rating). This rating combines consistent signals from two proprietary PTR measures of a stock’s attractiveness. Editas Medicine has a poor Appreciation Score of 27 and a very low Power Rating of 10, and the Lowest Value Trend Rating results.
Rating Review
In light of this new information and highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment